In agreement with our findings on immune checkpoint expression profiles of murine BCC‐like lesions, first proof‐of‐concept studies support a therapeutic benefit of anti‐PD‐1 treatment for patients with advanced or metastatic and SMO inhibitor‐resistant BCC [27, 28, 74]. The gene discussed is SMO; the disease is skin basal cell carcinoma.